Vemala Roopa, Gupta Bhaskar, Sivaprasad Sobha
Laser and Retinal Research Unit, King's College Hospital, London SE5 9RS, UK.
Clin Ophthalmol. 2010 Aug 19;4:913-6. doi: 10.2147/opth.s10259.
Neovascular age related macular degeneration (AMD) is relatively uncommon in the black population. We report the 12-month outcome of ranibizumab therapy in five black patients with choroidal neovascular membrane (CNV) secondary to AMD.
Retrospective analysis of a prospective audit database maintained for all patients on ranibizumab therapy in a retinal specialist unit that caters to a multi-ethnic cohort in London, United Kingdom.
At 12 months, all the 5 patients maintained stable vision (loss of less than 15 ETDRS letters). However, none of them gained more than 15 ETDRS letters. All eyes showed early subretinal fibrosis while 2 patients showed extended areas of retinal pigment atrophy.
Our case studies indicate that ranibizumab stabilizes the vision in black patients with CNV secondary to AMD but they tend to develop early subretinal fibrosis and retinal pigment atrophy.
新生血管性年龄相关性黄斑变性（AMD）在黑人人群中相对不常见。我们报告了5例继发于AMD的脉络膜新生血管膜（CNV）黑人患者接受雷珠单抗治疗12个月的结果。
对英国伦敦一个为多民族人群服务的视网膜专科单位中所有接受雷珠单抗治疗的患者的前瞻性审计数据库进行回顾性分析。
在12个月时，所有5例患者视力保持稳定（视力下降少于15个ETDRS字母）。然而，他们中没有一人视力提高超过15个ETDRS字母。所有患眼均出现早期视网膜下纤维化，2例患者出现视网膜色素萎缩范围扩大。
我们的病例研究表明，雷珠单抗可稳定继发于AMD的CNV黑人患者的视力，但他们往往会早期出现视网膜下纤维化和视网膜色素萎缩。
